The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysisTakuma Narita, Chikara Οhyama, Sadafumi Kawamura et al.|Medical Oncology|2016Cited by 49
Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysisTeppei Matsumoto, Chikara Οhyama, Shingo Hatakeyama et al.|Medical Oncology|2017Cited by 14
Can single positive core prostate cancer at biopsy be considered a low-risk disease?Hayato Yamamoto, Chikara Οhyama, Takuya Koie et al.|International Urology and Nephrology|2018Cited by 4
The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: A multi-institutional analysis.Takuya Koie, Takahiro Yoneyama, Teppei Ookubo et al.|Journal of Clinical Oncology|2017Cited by 0